Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Edwards Lifesciences (EW) Looks Good: Stock Soars 16.9%

Edwards Lifesciences Corp. EW was a big mover last session with its shares rising nearly 17% on the day. The upside came on the company’s April 2 announcement that the randomized PARTNER II Trial, aimed at comparing the SAPIEN XT valve to surgery in intermediate-risk patients, has successfully achieved its primary endpoint at two years. Further, on April 3, new data on patients at intermediate risk for open-heart surgery demonstrated that transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve was superior to surgery at one year on a composite primary endpoint of mortality, stroke and moderate or severe aortic regurgitation. Both these developments led to far more shares changing hands yesterday than in a normal session. The move continues the recent uptrend of the company as the stock has gained over 21% in the past one-month time frame.

This medical appliances and equipment company has seen 12 positive estimate revisions in the last 60 days. The Zacks Consensus Estimate has also moved considerably higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.

Edwards Lifesciences currently has a Zacks Rank #2 (Buy) and its Earnings ESP is positive.

Investors interested in the med-instruments space may also consider ABIOMED Inc. ABMD that carries a Zacks Rank #1 (Strong Buy).

Is EW going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ABIOMED INC (ABMD): Free Stock Analysis Report
 
EDWARDS LIFESCI (EW): Free Stock Analysis Report
 
To read this article on Zacks.com click here.